AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Emyria’s PTSD care program receives private insurer funding
- Partnership aims to expand access to trauma care
- New centres planned as part of national expansion
In a landmark development for mental health care in Australia, Emyria (ASX:EMD) has announced a major step forward in the delivery of advanced trauma treatment through its Empax program. The initiative, developed in partnership with Perth Clinic, has secured funding from Medibank Private (ASX:MPL), marking the first time a major private health insurer has backed a psychotherapy-led post-traumatic stress disorder (PTSD) treatment program in the country.
Under this two-year agreement, eligible Medibank members can now access Empax’s comprehensive psychological trauma care once admitted to Perth Clinic. This support removes significant financial barriers for individuals dealing with complex and persistent mental health challenges.
The Empax program, which integrates psychiatrist-supervised therapy, care coordination, and real-world data capture, offers a personalised treatment pathway for each patient. The therapy includes structured clinical protocols delivered by trained professionals, robust governance practices, and integrated data systems that support continuous improvement and long-term patient outcomes. Historically, similar care pathways provided by Emyria are valued between $20,000 and $30,000 per patient.
This strategic move comes at a time when mental health issues, particularly PTSD, affect approximately one in 11 Australians—often disproportionately impacting women and first responders. With increasing awareness about the urgent need for innovation in mental health, this partnership is being viewed as a turning point for more inclusive, data-driven therapeutic care.
The support from Medibank (MPL), an established player among ASX 200 today, further elevates the significance of this collaboration. It demonstrates how large institutions can play a pivotal role in reshaping healthcare delivery by facilitating access to promising new treatments. According to Emyria’s executive leadership, this is expected to lead to broader adoption across both the public and private health sectors.
An independent evaluation of the program’s clinical effectiveness and economic value will be conducted by Professor Paul Fitzgerald of the Australian National University. This assessment is aimed at building the case for expanded reimbursement and systemic integration.
Looking ahead, Emyria (EMD) is actively pursuing a national expansion strategy. This includes opening new Empax centres across key locations in eastern Australia and forming alliances with additional hospitals and insurers. The company is also leveraging its real-world data capabilities to support broader applications, including treatment-resistant depression and future regulatory engagement.
By securing this backing, Emyria positions itself at the forefront of next-generation mental health care in Australia—reinforcing the potential for ASX200-aligned companies to drive transformative change in healthcare delivery.
